International Team Tests Biomarker Combo for More Accurate Mesothelioma Diagnosis, According to Surviving Mesothelioma

Share Article

A team of mesothelioma researchers from Europe and Australia says a combination including three different biomarkers may offer a better way to diagnose the pleural cancer than current blood tests.

Using Biomarkers to Detect Mesothelioma

A New Blood Test for Mesothelioma?

The combination of the three biomarkers was the best predictor to differentiate malignant mesothelioma patients...

Scientists from university centers in Italy and Australia have just released their findings on a newly-developed mesothelioma blood test designed to detect three different kinds of mesothelioma biomarkers. Click here to read the full story on the Surviving Mesothelioma website.

Doctors with the Polytechnic University of Marche and the University of Trieste in Italy and Griffith University in Australia tested their ‘3-biomarker’ tool on the blood of 188 subjects, including 45 malignant mesothelioma patients, 99 people who had been exposed to asbestos but did not have mesothelioma, and 44 healthy people.

“The combination of the three biomarkers was the best predictor to differentiate malignant mesothelioma patients from asbestos-exposed subjects and healthy controls.,” writes lead researcher Lory Santarelli, MD, PhD, a toxicology expert at the Polytechnic University of Marche.

The research paper, published in the journal Lung Cancer, says the combination test overcomes some of the limits of the more common SMRP mesothelioma test.

“The SMRP test, while it is the most common mesothelioma blood test, is not sensitive enough to correctly identify every case of mesothelioma, especially in the early stages,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “Unfortunately, the longer a correct diagnosis is delayed, the worse the prognosis is likely to be.”

For the details of the proposed new test, see Using Biomarkers to Diagnose Mesothelioma Earlier, available now on the Surviving Mesothelioma website.

Santarelli, L, et al, “Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma”, September 25, 2015, Lung Cancer, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/26431916

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website